The cystic fibrosis market was valued at USD 5.12 Billion in 2024 driven by the adoption of gene therapies for the treatment of the condition across the 8 major markets. It is expected to grow at a CAGR of 20.10% during the forecast period of 2025-2034 and attain a market value of USD 31.97 Billion by 2034.
Base Year
Historical Year
Forecast Year
Advancements in gene-editing technologies like CRISPR and increasing R&D initiatives are revolutionizing cystic fibrosis treatment by addressing underlying genetic mutations, significantly driving market growth.
In July 2024, Sionna Therapeutics expanded its cystic fibrosis pipeline with clinical-stage compounds through a licensing agreement. This collaboration highlights the market’s focus on innovative therapies and strengthens its growth trajectory through enhanced treatment efficacy.
North America is expected to lead the market due to advanced healthcare infrastructure, robust R&D funding, and a strong focus on personalized medicine, making it a key driver of growth.
Cystic fibrosis, a genetic condition characterized by mucus accumulation, presents significant respiratory and nutritional challenges. The market is evolving rapidly, driven by breakthroughs in gene therapies and CFTR modulators. Key trends include a surge in clinical trials and strategic partnerships, enhancing treatment options. This transformation in the cystic fibrosis landscape is leading to improved patient outcomes and heightened awareness, ultimately fostering a more robust investment climate in this sector.
Advancements in Gene Therapy Drives Market Growth
Advancements in gene therapy, particularly through innovative gene-editing technologies like CRISPR, are revolutionizing treatment options for cystic fibrosis. By directly addressing the underlying genetic mutations, these therapies promise not only to enhance long-term patient outcomes but also to drive significant market growth. The continuous evolution of these methodologies underscores a shift towards more personalized medicine, positioning cystic fibrosis therapies at the forefront of the biotech industry's strategic development initiatives.
Several trends and developments are being observed in the market to enhance the current situation. Some of the noteworthy trends are as follows:
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Class
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Market Share by Route of Administration Set to Witness Significant Growth
Based on the route of administration, the market is divided into oral, and parenteral. Among these, the oral route is expected to hold a substantial share of the market in the coming years. Medicine like amoxicillin and clavulanic acid, cefdinir drive the market growth. Oral drugs can be consumed easily without the risk of invasive procedures to obtain effective treatment. This segment will likely experience growth over the forecast period, primarily driven by rising awareness and demand for treatment options that prioritize patient comfort and convenience.
Based on region, the market report covers the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, the United States is expected to dominate the market due to the rise in various respiratory disorders influencing cystic fibrosis, advanced technology, strong healthcare expenditure, increase in R&D activities. This region is poised for future growth with increasing due to rising health consciousness among consumers. Additionally, the government initiatives in healthcare infrastructure enhance competitiveness, making this region a key driver of market expansion in the forecast period.
The key features of the market report include patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies are:
Established in 2013 and headquartered in North Chicago, Illinois, USA, AbbVie is a leading biopharmaceutical company. For cystic fibrosis, AbbVie is actively involved in developing combination therapies targeting CFTR mutations, collaborating with Sionna Therapeutics to enhance treatment options through stabilizing the CFTR protein, aiming to improve efficacy and patient outcomes.
Founded in 1996 and headquartered in Basel, Switzerland, Novartis is a global healthcare leader. The company developed TOBI (tobramycin inhalation solution), an antibiotic therapy designed to treat chronic Pseudomonas aeruginosa infections in cystic fibrosis patients, significantly improving respiratory health and quality of life.
Established in 1896 and based in Basel, Switzerland, Roche is a pioneer in pharmaceuticals and diagnostics. For cystic fibrosis, Roche developed Pulmozyme (dornase alfa), a mucolytic agent that breaks down DNA in mucus, improving lung function and reducing respiratory infections in patients.
Founded in 1901 and headquartered in Tel Aviv, Israel, Teva is a leading generic drug manufacturer. Teva developed ProAir RespiClick (albuterol sulfate), an inhalation therapy used to treat bronchospasms in cystic fibrosis patients, enhancing airway clearance and respiratory function.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other companies include Vertex Pharmaceuticals, Gilead Sciences, Inc., Mylan NV, Allergan PLC, CHIESI Farmaceutici S.p.A., and PTC Therapeutics.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,969
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share